

# Karen E Knudsen

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/3018657/karen-e-knudsen-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

150  
papers

11,806  
citations

61  
h-index

106  
g-index

160  
ext. papers

14,038  
ext. citations

10.3  
avg, IF

6.28  
L-index

#	Paper	IF	Citations
150	DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 1697-708	59.2	1345
149	Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAs. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2015</b> , 112, E1106-15	11.5	307
148	Tailoring to RB: tumour suppressor status and therapeutic response. <i>Nature Reviews Cancer</i> , <b>2008</b> , 8, 714-24	31.3	263
147	Dual roles of PARP-1 promote cancer growth and progression. <i>Cancer Discovery</i> , <b>2012</b> , 2, 1134-49	24.4	260
146	AR, the cell cycle, and prostate cancer. <i>Nuclear Receptor Signaling</i> , <b>2008</b> , 6, e001	1	248
145	Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 4792-8	12.9	242
144	Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. <i>Cell</i> , <b>2018</b> , 174, 758-769.e9	56.2	234
143	The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. <i>Journal of Clinical Investigation</i> , <b>2010</b> , 120, 4478-92	15.9	223
142	Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer. <i>Trends in Endocrinology and Metabolism</i> , <b>2010</b> , 21, 315-24	8.8	220
141	A hormone-DNA repair circuit governs the response to genotoxic insult. <i>Cancer Discovery</i> , <b>2013</b> , 3, 1254-71.4	21.4	215
140	An evaluation of evidence for the carcinogenic activity of bisphenol A. <i>Reproductive Toxicology</i> , <b>2007</b> , 24, 240-52	3.4	212
139	PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. <i>Cancer Research</i> , <b>2014</b> , 74, 1651-60	10.1	204
138	Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. <i>Endocrine-Related Cancer</i> , <b>2011</b> , 18, 333-45	5.7	202
137	RB-dependent S-phase response to DNA damage. <i>Molecular and Cellular Biology</i> , <b>2000</b> , 20, 7751-63	4.8	199
136	The long non-coding RNA PCAT-1 promotes prostate cancer cell proliferation through cMyc. <i>Neoplasia</i> , <b>2014</b> , 16, 900-8	6.4	187
135	The meaning of p16(ink4a) expression in tumors: functional significance, clinical associations and future developments. <i>Cell Cycle</i> , <b>2011</b> , 10, 2497-503	4.7	186
134	Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of Reversion Mutations Associated with Resistance to PARP Inhibitors. <i>Cancer Discovery</i> , <b>2017</b> , 7, 999-1005	24.4	158

133	Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors. <i>Neoplasia</i> , <b>2015</b> , 17, 385-99	6.4	156
132	The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. <i>Journal of Clinical Investigation</i> , <b>2007</b> , 117, 218-28	15.9	152
131	Multiple G1 regulatory elements control the androgen-dependent proliferation of prostatic carcinoma cells. <i>Journal of Biological Chemistry</i> , <b>1998</b> , 273, 20213-22	5.4	147
130	Beyond DNA repair: DNA-PK function in cancer. <i>Cancer Discovery</i> , <b>2014</b> , 4, 1126-39	24.4	141
129	FOXA1: master of steroid receptor function in cancer. <i>EMBO Journal</i> , <b>2011</b> , 30, 3885-94	13	133
128	RB-pathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response. <i>Cell Cycle</i> , <b>2010</b> , 9, 4153-63	4.7	131
127	Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2014</b> , 89, 1038-1046	4	124
126	Alternative splicing of the cyclin D1 proto-oncogene is regulated by the RNA-binding protein Sam68. <i>Cancer Research</i> , <b>2010</b> , 70, 229-39	10.1	122
125	The xenoestrogen bisphenol A induces inappropriate androgen receptor activation and mitogenesis in prostatic adenocarcinoma cells. <i>Molecular Cancer Therapeutics</i> , <b>2002</b> , 1, 515-24	6.1	121
124	Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 991-999	2.2	117
123	DNA-PKcs-Mediated Transcriptional Regulation Drives Prostate Cancer Progression and Metastasis. <i>Cancer Cell</i> , <b>2015</b> , 28, 97-113	24.3	116
122	Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2006</b> , 103, 2190-5	11.5	112
121	Cyclin D1: mechanism and consequence of androgen receptor co-repressor activity. <i>Journal of Biological Chemistry</i> , <b>2002</b> , 277, 2207-15	5.4	107
120	Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 414-424	2.2	107
119	BAF57 governs androgen receptor action and androgen-dependent proliferation through SWI/SNF. <i>Molecular and Cellular Biology</i> , <b>2005</b> , 25, 2200-15	4.8	105
118	Hus1p, a conserved fission yeast checkpoint protein, interacts with Rad1p and is phosphorylated in response to DNA damage. <i>EMBO Journal</i> , <b>1998</b> , 17, 2055-66	13	104
117	Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor Function. <i>Molecular Cell</i> , <b>2015</b> , 58, 925-34	34.6	102
116	Transcriptional roles of PARP1 in cancer. <i>Molecular Cancer Research</i> , <b>2014</b> , 12, 1069-80	6.6	99

115	Ex vivo culture of human prostate tissue and drug development. <i>Nature Reviews Urology</i> , <b>2013</b> , 10, 483-5.5	96
114	The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 6916-6924	12.9 94
113	Hijacking the chromatin remodeling machinery: impact of SWI/SNF perturbations in cancer. <i>Cancer Research</i> , <b>2009</b> , 69, 8223-30	10.1 90
112	Compensation of BRG-1 function by Brm: insight into the role of the core SWI-SNF subunits in retinoblastoma tumor suppressor signaling. <i>Journal of Biological Chemistry</i> , <b>2002</b> , 277, 4782-9	5.4 90
111	Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 3562-70	12.9 85
110	Differential requirement of SWI/SNF for androgen receptor activity. <i>Journal of Biological Chemistry</i> , <b>2003</b> , 278, 30605-13	5.4 84
109	Targeting cell cycle and hormone receptor pathways in cancer. <i>Oncogene</i> , <b>2013</b> , 32, 5481-91	9.2 82
108	2,3,7,8-Tetrachlorodibenzo-p-dioxin blocks androgen-dependent cell proliferation of LNCaP cells through modulation of pRB phosphorylation. <i>Molecular Pharmacology</i> , <b>2004</b> , 66, 502-11	4.3 82
107	Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 2798-2811	2.2 80
106	Molecular pathogenesis and progression of prostate cancer. <i>Seminars in Oncology</i> , <b>2013</b> , 40, 244-58	5.5 78
105	Novel actions of next-generation taxanes benefit advanced stages of prostate cancer. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 795-807	12.9 75
104	Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer. <i>Cell Reports</i> , <b>2017</b> , 19, 2045-2059	10.6 72
103	Cyclin D1 splice variants: polymorphism, risk, and isoform-specific regulation in prostate cancer. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 5338-49	12.9 72
102	Prostate cancer. <i>Nature Reviews Disease Primers</i> , <b>2021</b> , 7, 9	51.1 72
101	Retinoblastoma tumor suppressor: where cancer meets the cell cycle. <i>Experimental Biology and Medicine</i> , <b>2006</b> , 231, 1271-81	3.7 71
100	The DNA methylation landscape of advanced prostate cancer. <i>Nature Genetics</i> , <b>2020</b> , 52, 778-789	36.3 71
99	USP22 regulates oncogenic signaling pathways to drive lethal cancer progression. <i>Cancer Research</i> , <b>2014</b> , 74, 272-86	10.1 68
98	Nuclear Pores Promote Lethal Prostate Cancer by Increasing POM121-Driven E2F1, MYC, and AR Nuclear Import. <i>Cell</i> , <b>2018</b> , 174, 1200-1215.e20	56.2 66

97	Bisphenol A facilitates bypass of androgen ablation therapy in prostate cancer. <i>Molecular Cancer Therapeutics</i> , <b>2006</b> , 5, 3181-90	6.1	66
96	Xenoestrogen action in prostate cancer: pleiotropic effects dependent on androgen receptor status. <i>Cancer Research</i> , <b>2005</b> , 65, 54-65	10.1	66
95	Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response in prostate cancer cells. <i>Cancer Research</i> , <b>2007</b> , 67, 6192-203	10.1	65
94	Cancer and the Circadian Clock. <i>Cancer Research</i> , <b>2019</b> , 79, 3806-3814	10.1	63
93	Targeting the BAF57 SWI/SNF subunit in prostate cancer: a novel platform to control androgen receptor activity. <i>Cancer Research</i> , <b>2008</b> , 68, 4551-8	10.1	63
92	Identification of ASF/SF2 as a critical, allele-specific effector of the cyclin D1b oncogene. <i>Cancer Research</i> , <b>2010</b> , 70, 3975-84	10.1	62
91	The SWI/SNF ATPase Brm is a gatekeeper of proliferative control in prostate cancer. <i>Cancer Research</i> , <b>2008</b> , 68, 10154-62	10.1	62
90	Androgen receptor corepressors and prostate cancer. <i>Endocrine-Related Cancer</i> , <b>2006</b> , 13, 979-94	5.7	61
89	Cyclin A is a functional target of retinoblastoma tumor suppressor protein-mediated cell cycle arrest. <i>Journal of Biological Chemistry</i> , <b>1999</b> , 274, 27632-41	5.4	61
88	The epigenetic modifier ubiquitin-specific protease 22 (USP22) regulates embryonic stem cell differentiation via transcriptional repression of sex-determining region Y-box 2 (SOX2). <i>Journal of Biological Chemistry</i> , <b>2013</b> , 288, 24234-46	5.4	59
87	Differential impact of RB status on E2F1 reprogramming in human cancer. <i>Journal of Clinical Investigation</i> , <b>2018</b> , 128, 341-358	15.9	58
86	A central domain of cyclin D1 mediates nuclear receptor corepressor activity. <i>Oncogene</i> , <b>2005</b> , 24, 431-44	9.2	57
85	Specificity of cyclin D1 for androgen receptor regulation. <i>Cancer Research</i> , <b>2003</b> , 63, 4903-13	10.1	57
84	A patient-derived explant (PDE) model of hormone-dependent cancer. <i>Molecular Oncology</i> , <b>2018</b> , 12, 1608-1622	7.9	54
83	Cyclin D1b is aberrantly regulated in response to therapeutic challenge and promotes resistance to estrogen antagonists. <i>Cancer Research</i> , <b>2008</b> , 68, 5628-38	10.1	53
82	The retinoblastoma tumor suppressor inhibits cellular proliferation through two distinct mechanisms: inhibition of cell cycle progression and induction of cell death. <i>Oncogene</i> , <b>1999</b> , 18, 5239-49	9.2	53
81	AR function in promoting metastatic prostate cancer. <i>Cancer and Metastasis Reviews</i> , <b>2014</b> , 33, 399-411	9.6	52
80	The cyclin D1b splice variant: an old oncogene learns new tricks. <i>Cell Division</i> , <b>2006</b> , 1, 15	2.8	52

79	Retinoblastoma tumor suppressor protein signals through inhibition of cyclin-dependent kinase 2 activity to disrupt PCNA function in S phase. <i>Molecular and Cellular Biology</i> , <b>2001</b> , 21, 4032-45	4.8	52
78	Detection of Activating Estrogen Receptor Gene () Mutations in Single Circulating Tumor Cells. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 6086-6093	12.9	50
77	Control of CCND1 ubiquitylation by the catalytic SAGA subunit USP22 is essential for cell cycle progression through G1 in cancer cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2018</b> , 115, E9298-E9307	11.5	50
76	MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 4201-4214	12.9	49
75	RB Loss Promotes Prostate Cancer Metastasis. <i>Cancer Research</i> , <b>2017</b> , 77, 982-995	10.1	47
74	mTOR is a selective effector of the radiation therapy response in androgen receptor-positive prostate cancer. <i>Endocrine-Related Cancer</i> , <b>2012</b> , 19, 1-12	5.7	44
73	PARP Inhibitors in Prostate Cancer. <i>Current Treatment Options in Oncology</i> , <b>2017</b> , 18, 37	5.4	42
72	Linking DNA Damage and Hormone Signaling Pathways in Cancer. <i>Trends in Endocrinology and Metabolism</i> , <b>2016</b> , 27, 216-225	8.8	42
71	Nuclear targeting of cyclin-dependent kinase 2 reveals essential roles of cyclin-dependent kinase 2 localization and cyclin E in vitamin D-mediated growth inhibition. <i>Endocrinology</i> , <b>2010</b> , 151, 896-908	4.8	41
70	Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing. <i>Prostate</i> , <b>2019</b> , 79, 333-339	4.2	41
69	Targeting the p300/CBP Axis in Lethal Prostate Cancer. <i>Cancer Discovery</i> , <b>2021</b> , 11, 1118-1137	24.4	41
68	Posttranscriptional Regulation of mRNA by HuR Facilitates DNA Repair and Resistance to PARP Inhibitors. <i>Cancer Research</i> , <b>2017</b> , 77, 5011-5025	10.1	40
67	Targeted radiosensitization of ETS fusion-positive prostate cancer through PARP1 inhibition. <i>Neoplasia</i> , <b>2013</b> , 15, 1207-17	6.4	39
66	Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer. <i>JAMA Oncology</i> , <b>2016</b> , 2, 471-80	13.4	38
65	Targeting PARP-1 allosteric regulation offers therapeutic potential against cancer. <i>Cancer Research</i> , <b>2014</b> , 74, 31-7	10.1	38
64	Outsmarting androgen receptor: creative approaches for targeting aberrant androgen signaling in advanced prostate cancer. <i>Expert Review of Endocrinology and Metabolism</i> , <b>2011</b> , 6, 483-493	4.1	38
63	The AR dependent cell cycle: mechanisms and cancer relevance. <i>Molecular and Cellular Endocrinology</i> , <b>2012</b> , 352, 34-45	4.4	35
62	Models of neuroendocrine prostate cancer. <i>Endocrine-Related Cancer</i> , <b>2015</b> , 22, R33-49	5.7	35

61	Functional specificities of Brm and Brg-1 Swi/Snf ATPases in the feedback regulation of hepatic bile acid biosynthesis. <i>Molecular and Cellular Biology</i> , <b>2009</b> , 29, 6170-81	4.8	35
60	Cyclin D1 is a selective modifier of androgen-dependent signaling and androgen receptor function. <i>Journal of Biological Chemistry</i> , <b>2011</b> , 286, 8117-8127	5.4	35
59	PARP-1 regulates DNA repair factor availability. <i>EMBO Molecular Medicine</i> , <b>2018</b> , 10,	12	35
58	Progesterone receptor-cyclin D1 complexes induce cell cycle-dependent transcriptional programs in breast cancer cells. <i>Molecular Endocrinology</i> , <b>2014</b> , 28, 442-57		34
57	Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes. <i>Journal of Clinical Investigation</i> , <b>2013</b> , 123, 493-508	15.9	33
56	Time to stratify? The retinoblastoma protein in castrate-resistant prostate cancer. <i>Nature Reviews Urology</i> , <b>2011</b> , 8, 562-8	5.5	31
55	Downregulation of Critical Oncogenes by the Selective SK2 Inhibitor ABC294640 Hinders Prostate Cancer Progression. <i>Molecular Cancer Research</i> , <b>2015</b> , 13, 1591-601	6.6	30
54	Cellular rewiring in lethal prostate cancer: the architect of drug resistance. <i>Nature Reviews Urology</i> , <b>2020</b> , 17, 292-307	5.5	30
53	The complex role of AR signaling after cytotoxic insult: implications for cell-cycle-based chemotherapeutics. <i>Cell Cycle</i> , <b>2007</b> , 6, 1307-13	4.7	30
52	Aberrant BAF57 signaling facilitates prometastatic phenotypes. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 2657-67.9	6.9	29
51	Unique bisphenol A transcriptome in prostate cancer: novel effects on ERbeta expression that correspond to androgen receptor mutation status. <i>Environmental Health Perspectives</i> , <b>2007</b> , 115, 1646-53	8.4	29
50	Targeting pioneering factor and hormone receptor cooperative pathways to suppress tumor progression. <i>Cancer Research</i> , <b>2012</b> , 72, 1248-59	10.1	28
49	Cell cycle-coupled expansion of AR activity promotes cancer progression. <i>Oncogene</i> , <b>2017</b> , 36, 1655-1668	9.2	26
48	RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 687-697	12.9	26
47	Sigma1 Targeting to Suppress Aberrant Androgen Receptor Signaling in Prostate Cancer. <i>Cancer Research</i> , <b>2017</b> , 77, 2439-2452	10.1	24
46	Patient-derived Models Reveal Impact of the Tumor Microenvironment on Therapeutic Response. <i>European Urology Oncology</i> , <b>2018</b> , 1, 325-337	6.7	23
45	USP22 Functions as an Oncogenic Driver in Prostate Cancer by Regulating Cell Proliferation and DNA Repair. <i>Cancer Research</i> , <b>2020</b> , 80, 430-443	10.1	22
44	Cell-cycle-dependent regulation of androgen receptor function. <i>Endocrine-Related Cancer</i> , <b>2015</b> , 22, 249-54	5.4	21

43	Therapeutic Challenge with a CDK 4/6 Inhibitor Induces an RB-Dependent SMAC-Mediated Apoptotic Response in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 1402-1414	12.9	21
42	Cyclin D1 repressor domain mediates proliferation and survival in prostate cancer. <i>Oncogene</i> , <b>2009</b> , 28, 1016-27	9.2	20
41	Mitogenic action of the androgen receptor sensitizes prostate cancer cells to taxane-based cytotoxic insult. <i>Cancer Research</i> , <b>2006</b> , 66, 11998-2008	10.1	20
40	SLC36A1-mTORC1 signaling drives acquired resistance to CDK4/6 inhibitors. <i>Science Advances</i> , <b>2019</b> , 5, eaax6352	14.3	17
39	DNA Damage Response in Prostate Cancer. <i>Cold Spring Harbor Perspectives in Medicine</i> , <b>2019</b> , 9,	5.4	16
38	Novel RB1-Loss Transcriptomic Signature Is Associated with Poor Clinical Outcomes across Cancer Types. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 4290-4299	12.9	15
37	The retinoblastoma tumor suppressor modulates DNA repair and radioresponsiveness. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 5468-5482	12.9	15
36	The circadian cryptochrome, CRY1, is a pro-tumorigenic factor that rhythmically modulates DNA repair. <i>Nature Communications</i> , <b>2021</b> , 12, 401	17.4	15
35	Caveolin-1 overexpression enhances androgen-dependent growth and proliferation in the mouse prostate. <i>International Journal of Biochemistry and Cell Biology</i> , <b>2011</b> , 43, 1318-29	5.6	14
34	Pleiotropic Impact of DNA-PK in Cancer and Implications for Therapeutic Strategies. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 5623-5637	12.9	13
33	Consequence of the tumor-associated conversion to cyclin D1b. <i>EMBO Molecular Medicine</i> , <b>2015</b> , 7, 628-47		13
32	The role of tumor suppressor dysregulation in prostate cancer progression. <i>Current Drug Targets</i> , <b>2013</b> , 14, 460-71	3	13
31	Postprostatectomy radiation therapy: an evidence-based review. <i>Future Oncology</i> , <b>2011</b> , 7, 1429-40	3.6	12
30	2,2-bis(4-chlorophenyl)-1,1-dichloroethylene stimulates androgen independence in prostate cancer cells through combinatorial activation of mutant androgen receptor and mitogen-activated protein kinase pathways. <i>Molecular Cancer Research</i> , <b>2008</b> , 6, 1507-20	6.6	11
29	An analysis of a multiple biomarker panel to better predict prostate cancer metastasis after radical prostatectomy. <i>International Journal of Cancer</i> , <b>2019</b> , 144, 1151-1159	7.5	11
28	Response and Resistance to Paradox-Breaking BRAF Inhibitor in Melanomas and. <i>Molecular Cancer Therapeutics</i> , <b>2018</b> , 17, 84-95	6.1	11
27	DNA-Dependent Protein Kinase Drives Prostate Cancer Progression through Transcriptional Regulation of the Wnt Signaling Pathway. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 5608-5622	12.9	10
26	Optimizing the Use of Telemedicine in Oncology Care: Postpandemic Opportunities. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 933-936	12.9	10



25	Decreased local immune response and retained HPV gene expression during chemoradiotherapy are associated with treatment resistance and death from cervical cancer. <i>International Journal of Cancer</i> , <b>2020</b> , 146, 2047-2058	7.5	9
24	RB/E2F1 as a Master Regulator of Cancer Cell Metabolism in Advanced Disease. <i>Cancer Discovery</i> , <b>2021</b> , 11, 2334-2353	24.4	9
23	A Randomized Phase II Study of Androgen Deprivation Therapy with or without Palbociclib in RB-positive Metastatic Hormone-Sensitive Prostate Cancer. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 3017-3027	12.9	7
22	Cyclin D1 goes metabolic: dual functions of cyclin D1 in regulating lipogenesis. <i>Cell Cycle</i> , <b>2012</b> , 11, 3533-47	4.7	6
21	Not So Fast: Cultivating miRs as Kinks in the Chain of the Cell Cycle. <i>Cancer Cell</i> , <b>2017</b> , 31, 471-473	24.3	5
20	AMPed up to treat prostate cancer: novel AMPK activators emerge for cancer therapy. <i>EMBO Molecular Medicine</i> , <b>2014</b> , 6, 439-41	12	5
19	Differential expression of $\alpha 5$ and $\alpha 6$ integrins in prostate cancer progression. <i>PLoS ONE</i> , <b>2021</b> , 16, e0244985	3.7	5
18	Double Trouble: Concomitant and Depletion Evokes Aggressive Phenotypes. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 1784-1786	12.9	2
17	Improvement in Therapeutic Efficacy and Reduction in Cellular Toxicity: Introduction of a Novel Anti-PSMA-Conjugated Hybrid Antiandrogen Nanoparticle. <i>Molecular Pharmaceutics</i> , <b>2018</b> , 15, 1778-1790	5.6	2
16	Hormone whodunit: clues for solving the case of intratumor androgen production. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 5343-5	12.9	2
15	Relevance of pRB Loss in Human Malignancies. <i>Clinical Cancer Research</i> , <b>2021</b> ,	12.9	2
14	Basic Science and Molecular Genetics of Prostate Cancer Aggressiveness. <i>Urologic Clinics of North America</i> , <b>2021</b> , 48, 339-347	2.9	2
13	IGF2 revs the steroidogenesis engine. <i>Endocrine-Related Cancer</i> , <b>2013</b> , 20, C19-21	5.7	1
12	Mutant p53 elicits context-dependent pro-tumorigenic phenotypes. <i>Oncogene</i> , <b>2021</b> ,	9.2	1
11	The Quandary of DNA-Based Treatment Assessment in De Novo Metastatic Prostate Cancer in the Era of Precision Oncology. <i>Journal of Personalized Medicine</i> , <b>2021</b> , 11,	3.6	1
10	The SAGA complex regulates early steps in transcription via its deubiquitylase module subunit USP22. <i>EMBO Journal</i> , <b>2021</b> , 40, e102509	13	1
9	Novel strategy for disease risk prediction incorporating predicted gene expression and DNA methylation data: a multi-phased study of prostate cancer. <i>Cancer Communications</i> , <b>2021</b> ,	9.4	1
8	Fusing transcriptomics to progressive prostate cancer. <i>American Journal of Pathology</i> , <b>2014</b> , 184, 2608-10.8	10.8	

- 7 Beyond the Cell Cycle: Implications of D-type Cyclin Deregulation in Prostate Cancer **2013**, 461-477
- 6 Androgen-mediated Control of the Cyclin D1-RB Axis: Implications for Prostate Cancer **2008**, 63-81
- 5 Androgen Mediated Regulation of the G1-S Transition in Prostate Cancer **2002**, 91-110
- 4 Splice Variants and Phosphorylated Isoforms of Cyclin D1 in Tumorigenesis. *Current Cancer Research*, **2018**, 91-109 0.2
- 3 Androgen Receptor Regulation of Prostate Cancer Progression and Metastasis **2011**, 277-309
- 2 Abstract IA9: Cross talk of the androgen receptor and DNA damage pathways: Molecular and translational prostate cancer relevance. *Cancer Research*, **2012**, 72, IA9-IA9 10.1
- 1 Potential Impact on Clinical Decision Making via a Genome-Wide Expression Profiling: A Case Report. *Urology Case Reports*, **2016**, 9, 51-54 0.5